Wechselwirkungen · Irbesartan Teva
Irbesartan Teva 75 mg film-coated tablets Irbesartan Teva 150 mg film-coated tablets Irbesartan Teva 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211783 · Präparat HOS-154755
Additional information on irbesartan interactions In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irbesartan (HOS-086921) hydrochlorothiazide (HOS-086937) digoxin (HOS-086172) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T15:49:00Z · SHA-256 9e693b92bbc186cab2665415d0e214a77d9d162abf8f5aa3c9c34e142728d200 · Passage d5f56398bd09e4fcd6c1fe623dd8c233bb6305b44eec08630d4d1e9d3c2bf8d1 · Zeichen 2686–3280 im Abschnitt